Maxim Group analyst Anthony Vendetti reiterated a Buy rating on Applied DNA Sciences (APDN) today and set a price target of $8.00. The company’s shares closed last Monday at $5.50, close to its 52-week low of $2.52.
According to TipRanks.com, Vendetti is a 1-star analyst with an average return of -3.2% and a 41.4% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Milestone Scientific, Ellex Medical Lasers, and Ra Medical Systems.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Applied DNA Sciences with a $8.00 average price target.
See today’s analyst top recommended stocks >>
Based on Applied DNA Sciences’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $2.66 million. In comparison, last year the company had a GAAP net loss of $3.23 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Applied DNA Sciences, Inc. engages in the provision of security solutions. It offers molecular-based technology solutions and services that can help protect products, brands, supply chains, and intellectual property of companies, governments, and consumers from theft, counterfeiting, fraud, and diversion.
Read More on APDN:
